Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

30. November 2015 09:56 ET | Quelle: BioSyent Inc.

BioSyent to Present at the LD Micro Main Event 2015 Investor Conference

TORONTO, ONTARIO--(Marketwired - Nov. 30, 2015) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that CEO René Goehrum will be making a presentation at the LD...
17. November 2015 08:00 ET | Quelle: BioSyent Inc.

BioSyent Pharma Announces the Canadian Launch of CYSVIEW(R) (Hexaminolevulinate Hydrochloride)

TORONTO, ONTARIO--(Marketwired - Nov. 17, 2015) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of...
11. November 2015 08:00 ET | Quelle: BioSyent Inc.

BioSyent Releases Results for Third Quarter and First Nine Months of 2015

TORONTO, ONTARIO--(Marketwired - Nov. 11, 2015) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its financial results for the three and nine months ending...
17. September 2015 09:15 ET | Quelle: BioSyent Inc.

BioSyent Named to the PROFIT 500 Ranking of Canada's Fastest-Growing Companies With a Five-Year Revenue Growth Rate of 1,086%

TORONTO, ONTARIO--(Marketwired - Sept. 17, 2015) - Editors Note: There is a photo associated with this press release. BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is...
19. August 2015 08:00 ET | Quelle: BioSyent Inc.

BioSyent Pharma Acquires Exclusive Rights For Cysview(R) In Canada

TORONTO, ONTARIO--(Marketwired - Aug. 19, 2015) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) announced today that its subsidiary BioSyent Pharma Inc. has signed an agreement with...
12. August 2015 08:00 ET | Quelle: BioSyent Inc.

BioSyent Releases First Six Months 2015 Results-Six Month Sales Up 25%; Pharma Sales Up 25%; EBITDA Up 31%; Net Income Up 30%; Return on Equity 40%

TORONTO, ONTARIO--(Marketwired - Aug. 12, 2015) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its Second Quarter (Q2 2015) and first half financial results for...
13. Mai 2015 16:21 ET | Quelle: BioSyent Inc.

CORRECTION FROM SOURCE: BioSyent Releases First Quarter 2015 Results - Sales Up 35%; Pharma Sales Up 38%; Ebitda up 92%; Diluted EPS $0.07, Up 75%; Net Income Up 88%

TORONTO, ONTARIO--(Marketwired - May 13, 2015) - A correction from source is being issued with respect to the BioSyent Inc. release that was disseminated May 13, 2015 at 08:00 ET. The...
13. Mai 2015 08:00 ET | Quelle: BioSyent Inc.

BioSyent Releases First Quarter 2015 Results - Sales Up 35%; Pharma Sales Up 38%; Ebitda up 92%; Diluted EPS $0.07, Up 75%; Net Income Up 88%

TORONTO, ONTARIO--(Marketwired - May 13, 2015) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its First Quarter (Q1 2015) financial results. Key highlights...
01. Mai 2015 16:01 ET | Quelle: BioSyent Inc.

BioSyent to Present at the 2015 Bloom Burton & Co. Healthcare Investor Conference

TORONTO, ONTARIO--(Marketwired - May 1, 2015) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that CEO René Goehrum will be making a presentation at the 2015...
10. April 2015 08:00 ET | Quelle: BioSyent Inc.

BioSyent Comments on Recent Market Activity

TORONTO, ONTARIO--(Marketwired - April 10, 2015) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) wishes to comment on the unusual recent market activity in its stock. The Company advises...

Vorherige Seite